Autopsy report · NCT01569438
The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)
Cause of deathNo reason given
Life of this trial
- Ran for about 2 years 1 month before it stopped.
- 107 participants enrolled.
- Results were posted on the registry 2 years 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Sponsor type
- Industry
- Conditions
- Bladder Pain Syndrome
- Interventions
- Gefapixant; Placebo
- Participants
- 107
- Sites
- 41
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.